Servicio de Urología, Hospital Universitario Central de Asturias.

This email address is being protected from spam bots, you need Javascript enabled to view it

Bladder cancer is a disease with a high prevalence due to its recurrence rate. Transurethral resection of the bladder (TURB) is the treatment in initial stages. Nevertheless, a high percentage of non-muscle-invasive tumors treated will have a recurrence 1-2 years afterwards. Adjuvant quemotherapy or immunotherapy after TURB has been administered in order to decrease the rate of recurrence and to prevent progression.

A prospectived, controlled and randomized study was performed. We included 100 patients with non-muscle-invasive and bladder tumors the low grade. All patients had initially a TURB performed and were randomized to either receive or not a single dose mitomycin C (MMC) in the immediate postoperatory.

All low grade tumors was less than 3 cm. Mean follow-up was 26.43 +/- 7.65 months. MMC was administered in 49 patients, of these, 67.3% had no recurrence and 32.7% had a non-muscle-invasive recurrence. Of the 51 patients in the non mitomycin, 51% had no recurrence while 47% had a non-muscle-invasive recurrence, and 2% had a muscle-invasive progression. We found significantly differences in time to recurrence among the two groups.

We found a greater time to recurrence in the group of single dose adjuvant MMC being this difference statistically significantly when comparing with the other group.

Article in Spanish

Written by:
Jalón Monzón A, Fernández Gómez JM, Escaf Bramada S, Alvarez Múgica M, García Rodríguez J, Regadera Sejas FJ.   Are you the author?

Reference:
Actas Urol Esp. 2008 Sep;32(8):811-20.

PubMed Abstract
PMID:19013980

UroToday.com Bladder Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!